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Abstract
Background: Despite being the most common pelvic gynecologic malignancy in industrialized countries, no targeted
therapies are available for patients with metastatic endometrial carcinoma. In order to improve treatment, underlying
molecular characteristics of primary and metastatic disease must be explored.
Methodology/Principal Findings: We utilized the mass spectrometric-based mutation detection technology OncoMap to
define the types and frequency of point somatic mutations in endometrial cancer. 67 primary tumors, 15 metastases
corresponding to 7 of the included primary tumors and 11 endometrial cancer cell lines were screened for point mutations
in 28 known oncogenes. We found that 27 (40.3%) of 67 primary tumors harbored one or more mutations with no increase
in metastatic lesions. FGFR2, KRAS and PIK3CA were consistently the most frequently mutated genes in primary tumors,
metastatic lesions and cell lines.
Conclusions/Significance: Our results emphasize the potential for targeting FGFR2, KRAS and PIK3CA mutations in
endometrial cancer for development of novel therapeutic strategies.
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Introduction
Despite being the most common pelvic gynecologic malignancy
in industrialized countries, no targeted therapies are available for
patients with metastatic endometrial carcinoma. Although 75%
are treated at an early stage, 15% to 20% recur. For patients with
advanced disease at diagnosis or recurrent disease, outcome is
poor. In order to improve treatment, underlying molecular
characteristics of primary and metastatic disease must be explored.
Furthermore, improved tools for correct stratification of patients
according to risk-groups and improved definitions of potential
targets for novel therapeutics are of great importance and much
work is undertaken to develop better criteria to select patients for
individualized therapies [1].
To assess the risk of recurrent disease, traditionally endometrial
cancer has been divided into two subgroups, type I and type II
carcinomas [2]. Type I endometrial carcinoma is associated with
good prognosis, low grade, endometrioid histology and rarely
metastasize to regional and distant sites [3]. In addition, type I
endometrial cancers are often hormone receptor positive with
PTEN and KRAS mutations. Type II endometrial carcinomas are
associated with poor prognosis, non-endometrioid histology, high
grade, loss of hormone receptors and altered expression of p53 and
p16. Still, the value of this classification to predict prognosis and
for treatment stratification is limited as 20% of type I endometrial
cancers recur and 50% of type II cancers do not [4].
Currently, conventional chemotherapy regimens and anti-
hormonal treatment are basis for adjuvant and systemic treatment
of recurrent or metastatic endometrial cancer as targeted therapies
are not yet available in the clinic. However, mutational profiles are
applied for selection of targeted therapeutics for several other
cancers and also applied for clinical trials stratification. Our
previous screening of a smaller number of endometrial cancer
patients identified somatic mutations in FGFR2, KRAS, PIK3CA,
PTEN, PT53 and CTNNB1 [5]. However, this study did not rule
out possible mutations in other known oncogenes that could be
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potentially interesting for targeted treatment of endometrial
cancer. Thus, the current study was undertaken to screen for a
large panel of known oncogenic mutations in a series of primary
and metastatic lesions from endometrial cancer patients using the
high-throughput method OncoMap [6,7]. OncoMap provides a
unique opportunity to simultaneously interrogate a large number
of known mutations in a large number of genes, thus providing the
opportunity to characterize the molecular subgroups of endome-
trial cancer with a potential relevance for targeting novel
therapeutics.
Methods
Ethics statement
All parts of the study have been approved according to
Norwegian legislation as well as international demands for ethical
review. The study was approved by the Norwegian Data
Inspectorate, Norwegian Social Sciences Data Services, and the
Western Regional Committee for Medical and Health Research
Ethics, REC West (NSD15501; REK 052.01). Patients were
included in the study after written informed consent approved by
the ethics committee (REK West).
Specimens
We have studied a total of 69 patients for mutations in 28
known oncogenes (Table 1). 23 of the included patients had
previously been screened for fewer oncogene mutations by another
method [5]. The patients were recruited from a population based
patient series of 701 patients with endometrial cancer prospec-
tively collected at Haukeland University Hospital, Norway. Age at
diagnosis, FIGO stage, histological subtype and grade, treatment
and follow-up was registered as previously reported [8]. Distribu-
tion of clinico-pathologic variable for the 69 investigated cases did
not differ significantly from the larger (n = 701) unselected patient
cohort (Table 2). Tissue was available from 67 primary tumors and
15 metastatic lesions from 9 patients of which 7 had corresponding
tissues from primary lesions available for comparison. The
majority of selected lesions were verified by frozen sections to
contain .80% malignant epithelial component with a minimum
cut off for inclusion of 50% purity.
Cell lines
Endometrial cancer cell lines Hec1A, Hec1B, KLE, RL95-2,
ECC1 were purchased from ATCC-LGC Standards, London,
UK, MFE-280, MFE-296, MFE3-19, EFE-184, AN3-CA were
from DSMZ, Germany and Ishikawa from Sigma-Aldrich,
St.Louis, MO. All cells were maintained in medium as recom-
mended by the supplier, supplemented with Penicillin/Strepto-
mycin (Sigma-Aldrich, St.Louis, MO).
OncoMap and DNA sequencing
DNA from primary and metastatic lesions was extracted from
fresh frozen biopsies. DNA was isolated by digestion over night at
65uC in lysis buffer containing proteinase K, followed by a
standard ethanol precipitation. DNA from 11 endometrial cancer
cell lines was extracted using Qiagen Tissue DNA kit according to
manufacturers protocol. DNA quantity was measured using the
Quant-iTTM PicogreenH Assay (Invitrogen) and high quality of the
DNA assured on a 0.7% agarose gel before genomic DNA was
amplified using the Repli-g Midi Kit (Qiagen, Germany)
according to manufacturers’ instructions. Amplified DNA was
diluted 1:10 in 1xTE buffer (pH 8.0) and after hydration for 24 h
at room temperature further diluted to a working concentration of
5 ng/ml in water. Mutations were detected in genome-amplified
DNA using a mass spectrometry-based single base extension
technique (Sequenom, Inc.) as previously described [7]. Primers
for additional assays to detect mutations described in several
cancer studies since 2008 [9,10,11,12,13] were designed using the
Sequenom Assay Design Software. Following amplification and
mutation site specific probe elongation analytes were spotted on
SpectroCHIPs I and masses detected using a Bruker matrix-
assisted laser desorption/ionization–time of flight mass spectrom-
eter (Sequenom). Spectra were manually reviewed using the Typer
4.0 Software (Sequenom). A list of the mutations included in
OncoMap and the corresponding amino acid changes is given in
Table S1.
To validate the proportion of the most frequently mutated
oncogenes detected by OncoMap, genomic DNA was extracted
from freshly frozen primary tumor tissue from 199 additional
patients. In total 264 patients were screened for point mutations in
KRAS (exon 2) and PIK3CA (exon 9 and 20) as described [14].
Details regarding primers and conditions are available upon
request. Sequencing reactions were analyzed on an ABI Prism
3100 genetic analyzer using the Sequencing Analysis software,
version 3.7.
Table 1. List of genes with number of mutations (n) screened
for in OncoMap1.
Gene Mutations (n)
ABL1 13
AKT2 2
ALK 13
BRAF 29
CDK4 2
DDR2 10
EGFR 55
EPHA3 16
EPHA5 6
ERBB2 22
ERBB4 9
FGFR1 3
FGFR2 15
FGFR3 11
FGFR4 11
FLT3 5
HRAS 16
JAK2 1
KDR 8
KIT 42
KRAS 19
MDM2 1
NRAS 18
NTRK1 8
NTRK3 10
PDGFRA 20
PIK3CA 16
RET 6
1Detailed information on gene mutations and nucleotide changes is given in
Table S1.
doi:10.1371/journal.pone.0052795.t001
Somatic Mutations in Endometrial Cancer
PLOS ONE | www.plosone.org 2 December 2012 | Volume 7 | Issue 12 | e52795
Oligonucleotide DNA microarray analyses
A microarray dataset corresponding to the 69 primary tumor
samples included in the OncoMap screen was generated. RNA
was extracted using the RNeasy Mini Kit (Qiagen, Hilden,
Germany) and hybridized to Agilent Whole Human Genome
Microarrays 44k (Cat.no. G4112F), according to the manufactur-
ers instructions. Arrays were scanned using the Agilent Microarray
Scanner Bundle and data were imported and analyzed in J-
Express software (Molmine, Norway). Median spot signal was used
as intensity measure. Expression data were normalized using
quantile normalization. Microarraydata have been deposited in
the ArrayExpress Archive database, http://www.ebi.ac.uk/
arrayexpress/ (ArrayExpress accession: E-MTAB-1358).
A SAM (Significance Analysis of Microarray) analysis between
grade I–II and grade III was performed to identify significantly
differentially expressed genes according to histologic grade. 306
genes were significantly differentially expressed (FDR,0.01)
between the two groups. Hierarchical clustering was performed
on this list of genes using weighted average linkage and Pearson
correlation as similarity measures. Clinico-pathological data and
mutational status were mapped manually to the cluster-tree to
visualize the distribution of mutation across the patient population.
Results
The OncoMap screen for 387 oncogenic mutations in 28
commonly mutated genes in cancer (Table S1) was applied in 67
primary and 15 metastatic endometrial carcinoma lesions as well
as 11 endometrial carcinoma cell lines and detected mutations in 7
of the investigated genes. We found that 27 patients (40.3%) had
point mutations in one single gene, while 4 patients (6.0%) had
mutations in 2 genes. Among the seven genes with detected
somatic mutations in primary and metastatic lesions, KRAS
(17.9%), PIK3CA (14.6%) and FGFR2 (10.4%) were the most
frequently mutated, while mutations in BRAF (1.5%), EGFR
(1.5%), HRAS (1.5%) and NRAS (1.5%) were rare. The frequencies
of KRAS and PIK3CA mutations were validated by DNA
sequencing in 264 primary tumors (Table 3). FGFR2 mutation
frequency had been validated previously [5]. The most common
single mutation found by OncoMap screening was FGFR2
aaS252W (9.0%), however the most frequently mutated gene
was KRAS (17.4%) (Table 3). The OncoMap screen of the 11
established endometrial cancer cell lines identified as expected
KRAS G12D and PIK3CA G1049R mutations in both Hec1A and
Hec1B, while FGFR2 mutation S252W was found in MFE280 and
MFE319. Additionally, two PIK3CA mutations were identified in
MFE280 and MFE296 (E545K and P539R, respectively). We did
not find any of the cell lines to have mutations in any of the other
genes included in the OncoMap panel.
To explore a possible link between type of mutations and gene
expression patterns in primary tumors, a hierarchical cluster
analysis of 306 genes significantly differentially expressed (SAM
analysis, FDR,0.01) according to histologic grade was performed.
We found that there was no significant association between specific
oncogene mutations and patient clusters based on transcriptional
signatures (Figure 1). This finding appears to be in line with our
previous report on a smaller data set applying an earlier
generation of mRNA genearrays, with no enrichment for PIK3CA
mutations in the patient cluster capturing aggressive phenotype
[15].
To further investigate if mutation pattern changed during
disease progression, 15 metastatic lesions from 9 patients from
which seven had primary tumors available for comparison, were
Table 2. Clinico-pathologic characteristics of 69 endometrial cancer patients screened in OncoMap compared to the whole
population from the same region.
Variable OncoMap n (%) Total n =69* Whole population n (%) Total n=7011
Age, median 65 65
Menopause
Pre-/Peri- 13 (19) 87 (12)
Post- 56 (81) 614 (88)
FIGO-09 stage
I–II 56 (81) 577 (82)
III–IV 13 (19) 124 (18)
Histologic type
Endometrioid 58 (84) 551 (79)
Non-endometrioid 11 (16) 150 (21)
Histologic grade
Grade 1/2 46 (68) 449 (65)
Grade 3 22 (32) 243 (35)
Metastatic nodes
Negative 38 (83) 484 (88)
Positive 8 (17) 64 (12)
ERa
Positive 49 (75) 365 (77)
Negative 16 (25) 111 (23)
*Missing (n = 69); Grade: 1, Metastatic nodes: 23, ERa: 4.
1Missing (whole population); Grade: 9, Metastatic nodes: 153, ERa: 225.
doi:10.1371/journal.pone.0052795.t002
Somatic Mutations in Endometrial Cancer
PLOS ONE | www.plosone.org 3 December 2012 | Volume 7 | Issue 12 | e52795
analyzed for mutations. KRAS, PIK3CA and FGFR2 were found to
be the most frequently mutated genes also in metastatic lesions,
with no significant increase in mutation frequency (Table 4). In
two cases, mutations were detected in the metastatic lesions but
not in the primary lesion, while one case with mutation in the
primary lesion had no detectable mutation in the metastatic lesion.
The small sample set available for this analysis, tumor heteroge-
neity and differences in stromal contamination should call for
caution in the conclusions.
Discussion
Activating mutations in specific proto-oncogenes may confer
oncogene-addiction. Such mutations have been identified in
several genes and may drive malignant disease progression. This
principal for oncogene-addiction can be exploited to develop new
targeted therapies [16]. Currently, mutational profiles are applied
for selection of targeted therapeutics for e.g. BRAF inhibitors in
malignant melanoma [17] and BRAF and EGFR targeting in
lung- and colorectal cancers [18,19]. For endometrial cancer,
none of the novel targeted therapeutics is available in the clinic at
present. However, several ongoing clinical trials aim at exploiting
Table 3. Frequency of mutations in 671 primary lesions from
endometrial cancer patients.
Gene aa OncoMap n=67
2
Validated n=264
(%)
n (%)
FGFR2 S252W 6 9
P253R 1 1.5
Total: 7 10.4 12.3 [5]3
KRAS G12C 3 4.5
G13D 3 4.5
G12D 3 4.5
G12A 1 1.5
total Exon 2 10 16.1 14.7
Q61H 2 3.0
Total: 12 17.9
PIK3CA R88Q 2 3.0
Q546K 2 3.0
E545K 2 3.0
P539R 1 1.5
total Exon 9 7 7.5 5.8
M1043I 1 1.5
H1047R 1 1.5
total Exon 20 2 3.2 8.8
Total: 9 11.9 14.6
BRAF F468C 1 1.5
EGFR T790M 1 1.5
HRAS G125 1 1.5
NRAS Q61L 1 1.5
1data missing for 2 primary tumors, n: number of mutated samples.
223 of the samples previously subjected to DNA sequencing of all exons of 89
tyrosine kinase genes and 19 additional known oncogenes and tumor
suppressor genes as reported [5].
3Validated in a dataset independent of the present study.
doi:10.1371/journal.pone.0052795.t003
Figure 1. Mutational status is not reflected in distinct patient
clusters related to phenotype. A hierarchical clustering of 306
significantly differentially expressed genes between grade I–II and
grade III was mapped with clinico-pathological data and mutational
status to visualize the distribution of mutation across the patient
population. Green square color indicate good prognosis groups (Grade
I–II, FIGO I–II, endometrioid type, ERa positivity) and no detected
mutation in indicated gene, Red square color indicate poor prognosis
groups (Grade III, FIGO III–IV, non-endometrioid types, ERa negativity)
and detected mutation in indicated gene. Black square: data missing.
doi:10.1371/journal.pone.0052795.g001
Somatic Mutations in Endometrial Cancer
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targets supported by recent comprehensive molecular profiling of
primary endometrial carcinoma lesion [1], dominated by trials
targeting the phosphatidylinositol 3-kinase (PI3K)/AKT/mam-
malian target of rapamycin (mTOR) or FGFR2. However, to our
knowledge, no previous study has reported as comprehensive
mutational data for a large panel of oncogenes in endometrial
cancers including metastatic lesions.
A large number of oncogene mutations has been identified to be
important in cancer development. Recently, several papers have
reported the usefulness of the high-throughput genotyping
platform OncoMap to screen for mutations in a large panel of
known cancer oncogenes [6,20,21,22]. The high degree of
concordance between our findings using OncoMap for the
investigated genes and the validated frequency in the present
study as well as previously published mutation frequencies in
endometrial cancer samples based on traditional sequencing, is
assuring. Using OncoMap we found that 40.3% of the analyzed
endometrial cancer samples harbored at least one mutation. Of
the 28 oncogenes included, mutations were only found at high
frequency (.10%) in KRAS, PIK3CA and FGFR2. These genes
have been linked to endometrial cancer previously, both by us
[5,15] and others [23,24].
In the present study, the S252W mutation in FGFR2 was
identified as the most frequent single mutation (9%) in endometrial
cancer. The somatic FGFR2 mutations include the S252W and
P253R alleles, where autosomal dominant mutations are associ-
ated with the congenital developmental disorder Apert syndrome
[25]. We, and others [26], have previously linked these mutations
to endometrial cancer, through increased tumor cell survival and
anchoring independent growth in endometrial cancer cell lines,
and indicated the potential for FGFR2 inhibitors in mutated cell
lines [5]. It has also been reported that FGFR2 inhibitors induce
cell death in endometrial cancer cells despite PTEN inactivating
mutations [27]. The frequency of FGFR2 mutations detected in
the present OncoMap screen of 10.4% is in concordance with our
previous findings from 122 endometrial cancer patients from the
same region, finding FGFR2 to be mutated in 12.3% [5]. Recently,
a frequency in this range of 10.3% was also published by others
[23].
Several of the PIK3CA mutations were detected at relatively low
frequencies (,3%), however the total frequency of any detected
PIK3CA mutations was 13.4%. We have validated this frequency
of point mutations in PIK3CA (exon 9 and 20) in 14.6% in a cohort
of 264 endometrial cancer patients. This is consistent with the
reported mutational frequency of PIK3CA in endometrial carci-
noma in the COSMIC database for PIK3CA mutations tested for
in OncoMap [28]. A potential relevance for targeting therapy in
patients harboring PIK3CA mutations was recently supported in a
study demonstrating higher response rate to PI3K/AKT/mTOR
inhibitors for patients with mutated compared to wild type PIK3CA
in breast and gynecologic malignancies [29].
KRAS mutations were found in 17.9% of the cases, with high
frequency of point mutations in exon 2 (G12A, G12C, G12D and
G13D), validated in 264 endometrial cancer patients (14,7%; [14])
and also in line with previous studies (18%; [30]). KRAS mutations
have been associated with low grade, and endometrioid histologic
subtype, although not with prognosis [31,32]. Interestingly, KRAS
and FGFR2 mutations were found to be mutually exclusive, in line
with a previous report [23]. In terms of therapy KRAS mutational
status has been linked to EGFR inhibitor resistance in colorectal
cancer [33], but further studies are needed in endometrial
carcinoma to explore such potential link.
In line with the present study, we previously reported a low
frequency (2%) of mutations in BRAF in endometrial cancer [30].
Interestingly, with the exception of a few mutations in NRAS,
HRAS, EGFR and BRAF (1.5%), no other hot-spot mutations were
identified in the remaining 21 oncogenes screened for, neither in
primary tumors nor in metastatic lesions.
The present work used a version of OncoMap covering 387
mutations in a total of 28 different oncogenes. In endometrial
Table 4. Mutational status in primary endometrial cancers and corresponding metastatic lesions.
Primary Tumors Corresponding metastatic lesions
ID Gene AA Met ID Gene AA Site of met
499 n.m.d1 499a PIK3CA R88Q Spleen
394 n.m.d 394a n.m.d Vagina
1749 Data missing 1749a n.m.d Lymph node
1749b n.m.d Lymph node
1749c n.m.d Lymph node
492 Data missing 492a PIK3CA E545K Oment
492b PIK3CA E545K Gastric
279 PIK3CA P539R 279a n.m.d Oment
1393 PIK3CA R88Q 1393a PIK3CA R88Q Cervix
1406 PIK3CA FGFR2 E545K S252W 1406a FGFR2 S252W Cervix
1406b FGFR2 S252W Vagina
PIK3CA E545K
621 FGFR2 S252W 621a n.m.d Parametrium
1495 KRAS G12D 1495a KRAS G12D Vagina
1495b KRAS G12D Ovary
1495c KRAS G12D Ovary
1n.m.d: no mutation detected.
doi:10.1371/journal.pone.0052795.t004
Somatic Mutations in Endometrial Cancer
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carcinomas, the oncogenes CTNNB1 and tumor suppressor genes
PTEN and P53 have also been reported to be frequently mutated
[34,35] but were not included in the present sceen and can
therefore not be accounted for. Among the included genes and
mutations, we have identified and validated KRAS, PIK3CA and
FGFR2 to be the most frequently mutated oncogenes in
endometrial cancer. Although transcriptional signature pattern
according to histologic grade did not identify any distinct
subgroups linking any of the mutations to phenotype, PIK3CA,
KRAS and FGFR2 mutations may still be of relevance for targeting
novel therapeutics in endometrial cancer. Nevertheless, more
knowledge regarding functional aspects of the different mutations
and their implications for response to drugs will be important to
guide further selection of patients for molecularly based clinical
trials.
Supporting Information
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